Scinai says new CDMO deal and financing extend runway toward 2027-2028

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) issued a shareholder letter from CEO Amir Reichman dated October 20, 2026, describing how a recent CDMO agreement and completed financing affect the company's outlook. Reichman said last week's CDMO agreement and completed financing materially strengthen Scinai's ability to execute its strategy, with the agreement expanding contracted business and visibility into workload, and the financing providing resources to deliver that work and compete for additional projects.¹

On the CDMO deal, Scinai disclosed that its new agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms¹, and that it expands an existing customer relationship¹. The company said as of October 20, 2026, its Committed Customer Orders stood at approximately $8.1 million, compared with $1.9 million at year-end 2025, an increase of more than 300%¹.

The program covers analytical work, manufacturing readiness, clinical supply, stability testing and a prefilled-syringe presentation, with development and activities supporting an Investigational New Drug application underway in 2026, with clinical manufacturing planned to begin in January 2027¹. The agreement also contemplates additional, uncommitted clinical manufacturing in late 2027 and the first half of 2028, with an indicative service-fee value of approximately $5.85 million, excluded from the $5.1 million base commitment and Committed Customer Orders¹.

On financing, Reichman noted on October 13 the company raised approximately $1.67 million in net proceeds through its standby equity purchase agreement with YA II PN, Ltd., an affiliate of Yorkville Advisors¹, and that the separately announced $4 million financing generated approximately $3.6 million in net proceeds after transaction expenses, bringing combined net proceeds to approximately $5.3 million, excluding any future proceeds from exercises of the newly issued warrants.¹

Reichman said under current operating and CDMO sales plans, cash resources and expected customer payments support an estimated operating runway to late 2027, which could extend into the third quarter of 2028 if later project phases are activated and delivered, though both estimates depend on sales, timely collections and successful execution.¹